Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Low-Risk Patients: A Critical Appraisal of the DEDICATE Trial in the Context of Current Evidence
Main Article Content
Abstract
The expansion of transcatheter aortic valve implantation (TAVI) to patients with severe aortic stenosis and low surgical risk represents a paradigm shift in cardiovascular medicine, yet it remains a subject of intense scrutiny. The DEDICATE-DZHK6 trial emerges as a pivotal, investigator-initiated, industry-independent, pragmatic randomized controlled trial designed to address the limitations of previous landmark studies. This comprehensive review critically appraises the DEDICATE trial, juxtaposing its findings and design against the established evidence from the PARTNER 3, Evolut Low Risk, NOTION, and UK TAVI trials. We dissect the methodological strengths of DEDICATE, including its pragmatic design, allowance for any contemporary device, and freedom from commercial funding, while also examining its limitations, such as the significant crossover rate and the potential confounding effects of the COVID-19 pandemic. The analysis extends to the profound implications for clinical practice and the latest 2025 ESC/EACTS guidelines, emphasizing the critical shift towards a Heart Team-based, lifetime management strategy. Finally, we propose essential future research directions, advocating for long-term durability data, focused subgroup analyses, and robust quality-of-life assessments to guide the optimal, individualized treatment of this growing patient population.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Blankenberg S, Seiffert M, Vonthein R, et al. Transcatheter or surgical treatment of aortic-valve stenosis. N Engl J Med. 2024;390(17):1572-1583.
II. Narayan P. DEDICATE trial: the devil lies in the definition of "low risk". Indian J Thorac Cardiovasc Surg. 2024;40(4):507-510.
III. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.
IV. León MB, Mack MJ, Pibarot P, et al. Transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years. N Engl J Med. 2026;394(8):773-783.
V. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949-1960.
VI. García-Villarreal OA. PARTNER 3 at 7 years: temporal heterogeneity, endpoint architecture, and the limits of long-term equivalence. Cir Card Mex. 2026;11(2):54-58.
VII. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706-1715.
VIII. Forrest JK, Yakubov SJ, Deeb GM, et al. 5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Cardiol. 2025;85(15):1523-1532.
IX. Forrest JK, Deeb GM, Yakubov SJ, et al. Evolut Low Risk trial: six-year outcomes and reintervention analysis. J Am Coll Cardiol. 2026.
X. Thyregod HGH, Steinbrüchel DA, Ihlemann N, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the All-Comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65(20):2184-2194.
XI. Thyregod HGH, Ihlemann N, Jørgensen TH, et al. Five-year clinical and echocardiographic outcomes from the NOTION randomized clinical trial in patients at lower surgical risk. Circulation. 2019;139(24):2714-2723.
XII. Thyregod HGH, Jørgensen TH, Ihlemann N, et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J. 2024;45(13):1116-1124.
XIII. Ferrarotto L, Jørgensen TH, Søndergaard L, et al. Ten years of transcatheter aortic valve implantation in the NOTION study: the good and the bad. Eur Heart J Suppl. 2025;27(Suppl 3):iii153-iii155.
XIV. Serruys PW, Modolo R, Reardon M, et al. One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. EuroIntervention. 2018;14(8):877-883.
XV. Ludwig S, Seiffert M, Vonthein R, et al. Transcatheter or surgical treatment of patients with aortic stenosis at low to intermediate risk: an individual participant data meta-analysis. JAMA Cardiol. 2025;10(11):1175-1185.
XVI. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;77(4):e25-e197.
XVII. Généreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42(19):1825-1857.
XVIII. Curzen N, et al. Cost-utility analysis of TAVI versus surgery in low-risk patients with severe aortic stenosis in the UK. Appl Health Econ Health Policy. 2026.
XIX. Muller Moran HR, Eikelboom R, Lodewyks C, et al. Two-year outcomes from the PARTNER 3 trial: where do we stand? Curr Opin Cardiol. 2020;35(2):141-147.
XX. Bowdish ME, Habib RH, Kaneko T, Thourani VH, Badhwar V. Cardiac surgery after transcatheter aortic valve replacement: trends and outcomes. Ann Thorac Surg. 2024;118(1):155-162.
XXI. Makkar RR, Thourani VH, Mack MJ, et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy. J Am Coll Cardiol. 2020;75(24):3003-3015.